Unknown

Dataset Information

0

Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules.

ABSTRACT: Pemetrexed, a new multitarget antifolate antineoplastic agent, has significantly improved the overall survival in nonsquamous non-small-cell lung cancer patients. Presently, pemetrexed is recommended for first line treatment in combination with platinum derivatives, for second line treatment as a single agent and, more recently, as maintenance treatment after first line chemotherapy. In this article we critically appraise the status of pemetrexed including pharmacodynamics, pharmacokinetics, toxicity, and the cost effectiveness of pemetrexed, as well as the predictive biomarkers for pemetrexed based chemotherapy.

SUBMITTER: Li X 

PROVIDER: S-EPMC4057332 | biostudies-other | 2014

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules.

Li Xin X   Wei Sen S   Chen Jun J  

OncoTargets and therapy 20140606

Pemetrexed, a new multitarget antifolate antineoplastic agent, has significantly improved the overall survival in nonsquamous non-small-cell lung cancer patients. Presently, pemetrexed is recommended for first line treatment in combination with platinum derivatives, for second line treatment as a single agent and, more recently, as maintenance treatment after first line chemotherapy. In this article we critically appraise the status of pemetrexed including pharmacodynamics, pharmacokinetics, tox  ...[more]